Optometrists in Harrisville, MI Accepting Medicare
3 Optometrists found. Showing 1 - 3
 Harrisville Eye Care Optometrist Medicare: Not Enrolled in Medicare Practice Location: 300 North Us-23, Harrisville, MI 48740 Phone: 989-724-7440 Fax: 989-724-7531 |
 Dr. Benjamin David Dietrich, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 300 N State St, Harrisville, MI 48740 Phone: 989-724-7440 Fax: 989-724-7531 |
Harrisville Eye Care Optometrist Medicare: Medicare Enrolled Practice Location: 300 N State St, Harrisville, MI 48740 Phone: 989-724-7440 Fax: 989-724-7531 |
News Archive
Omega Healthcare Investors agrees to sell common stock under equity distribution agreement with BofA Merrill Lynch
Omega Healthcare Investors, Inc. today announced that it has agreed to sell shares of its common stock having an aggregate offering price of $33.3 million pursuant to a terms agreement entered into under the equity distribution agreement, dated June 12, 2009, between the Company and BofA Merrill Lynch in connection with the company's previously reported $100 million Equity Shelf Program.
Minimally invasive implant procedure effective for patients with sacroiliac joint dysfunction
A minimally invasive implant procedure is highly effective in reducing pain and disability for patients with sacroiliac joint (SIJ) dysfunction, reports a clinical trial in the November issue of Neurosurgery, official journal of the Congress of Neurological Surgeons, published by Wolters Kluwer.
QIAGEN's therascreen EGFR Mutation Detection Kit receives Japanese regulatory approval
QIAGEN today announced the regulatory approval of its therascreen EGFR Mutation Detection Kit RGQ in Japan. EGFR, the epidermal growth factor receptor, has been shown to play an important role in certain cancers and is the target of many new anticancer drugs.
Cheap drug that prevents bleeding may save 100,000 lives each year: Study
Researchers have shown that a cheap and easy to use drug that stops bleeding may save up to 100,000 lives each year from injuries associated with road accidents and violence. The study was published this Tuesday in the acclaimed international journal The Lancet and was conducted by doctors at the London School of Hygiene and Tropical Medicine.
OncoSec reports positive interim data from ElectroChemotherapy Phase IV head and neck cancer study
OncoSec Medical Inc., which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, today announced positive interim analysis of data from 81 subjects in a Phase IV study of primary and locally recurrent squamous cell carcinoma of the head and neck (HNSCC) treated with OMS ElectroChemotherapy in Europe.
› Verified 4 days ago